Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges – RP Digital

Business

Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges

July 15, 20251 min0

Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges

Source link

rpdigital

Leave a Reply Cancel reply

Related Articles

BancFirst declares quarterly dividend and trust interest payment

rpdigitalAugust 28, 20250

Jefferies raises Ollie's Bargain Outlet stock price target to $135 on strong growth

rpdigitalAugust 28, 20250